Adcendo
Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment
$75MSeries C
Role not disclosedLoading investors…
Activity from announced rounds
Pitching Pontifax Venture Capital? Send the deck from a free RoundOS data room and see which pages they read.